1075237-97-6

Usage

Uses

Used in Pharmaceutical Development:
Beta-lactamase-IN-1 is used as a therapeutic agent for combating antibiotic resistance. It serves to enhance the effectiveness of existing beta-lactam antibiotics by inhibiting the beta-lactamase enzymes that would otherwise render these drugs ineffective against resistant bacteria.
Used in Combination Therapies:
In the medical industry, beta-lactamase-IN-1 is utilized as a component in combination therapies designed to tackle antibiotic-resistant bacteria more effectively. Its inclusion in such therapies aims to broaden the spectrum of activity and reduce the likelihood of resistance development.
Used in Antibiotic Research:
Beta-lactamase-IN-1 is also used as a research tool in the ongoing quest to understand and overcome antibiotic resistance. It aids scientists in studying the mechanisms of beta-lactamase enzymes and in developing strategies to counteract their resistance effects.
Used in Diagnostics:
In the field of diagnostics, beta-lactamase-IN-1 may be employed to identify bacteria that produce beta-lactamase enzymes, helping in the rapid determination of antibiotic resistance profiles and guiding the selection of appropriate treatment options.

Upstream product

• 1075237-93-2 ethyl N-[2-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-6-(methyloxy)-3-pyridinyl]glycinate 
• 1075237-94-3 4-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-1,4-dihydropyrido[2,3-b]pyrazin-3(2H)-one 
• 1075237-92-1 N²-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-2,3-pyridinediamine 
• 1075237-91-0 N-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-3-nitro-2-pyridinamine 
• 38533-61-8 2-chloro-6-methoxy-3-nitropyridine 
• 757186-96-2 2-{[6-(methyloxy)-3-nitro-2-pyridinyl]amino}-1,3-propanediol 
• 1075237-96-5 4-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)pyrido[2,3-b]pyrazin-3(4H)-one 

Downstream Products

• 1075236-89-3 gepotidacin 
• 1075234-98-8 (2R)-2-({4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione benzoate 
• 1075235-01-6 (2S)-2-({4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione benzoate 
• 1197396-93-2 (2E)-3-(2,5-difluorophenyl)-N-{1-[(3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl)methyl]-4-piperidinyl}-2-propenamide 
• 1197396-96-5 2-[(4-{[2-(3,4-dichlorophenyl)ethyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione 

Relevant academic research and scientific papers

Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones

The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.

TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS

Compounds of Formula (I) or a pharmaceutically acceptable salt or N-oxide thereof; Formula (I) (relative stereochemistry shown) wherein: Z1, Z2 , L are as defined, U represents a cyclic group selected from: phenyl, pyridyl, pyridazin

TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS

Tricyclic nitrogen containing compounds and their use as antibacterials. Z1and Z2 are independently selected from CH and N.